secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274005
Event type: earnings
Sentiment:  neutral
Materiality: 0.30
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences reports Q3 2023 earnings; no financial details in furnished transcript
--------------------------------------------------------------------------------

- Company announced preliminary financial results for quarter ended September 30, 2023.
- Conference call held on November 7, 2023; transcript furnished as Exhibit 99.1.
- Transcript excerpt provided does not include specific revenue, EPS, or guidance figures.
- CEO Wenbin Jiang and CFO Patrik Jeanmonod participated in the call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523274005/0001193125-23-274005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523274005/d295364d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer